FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE)

Completed · Phase 2

Conditions studied: Prostate Cancer

In brief

This clinical trial will determine whether the addition of radiotherapy to standard of care systemic therapy improves objective progression-free survival compared to systemic therapy alone in patients with oligometastatic castration-resistant prostate cancer.

Key facts

Study ID

NCT03556904

Run by

University of Michigan Rogel Cancer Center

People needed

14

Starts

2018-12-10

Expected to finish

2023-07-28

Last updated by the study team

2026-01-15

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Subjects must have biopsy-confirmed adenocarcinoma of the prostate
• Subjects must discontinue any prior systemic therapies (excluding GnRH agonist/antagonists) without PSA withdrawal effects if using first generation anti-androgens. Luteinizing hormone-releasing hormone (LHRH) analogues must be continued if they have not undergone orchiectomy. (Subjects who recently started systemic therapy for metastatic castration-resistant prostate cancer (mCRPC) are eligible to enroll if new therapy was started ≤ 14 days to consent date.)
• Subjects must have progressive metastatic castration-resistant prostate cancer based on at least one of the following criteria while having castrate levels (<50 ng/dL) of testosterone:
• A) PSA progression defined as a 25% increase over baseline value with an increase in the absolute value of at least 2.0 ng/mL that is confirmed by another PSA level with a minimum of a 1-week interval.
• B) Progression of bidimensionally measurable soft tissue or nodal metastasis by CT scan or MRI based on RECIST criteria
• C) Progression of bone disease on bone scan as defined by two new lesions arising
• Subjects must have oligometastatic prostate cancer, defined as between 1 and ≤5 treatment sites that can be treated within a radiotherapy treatment field.
• Subjects must be medically fit to undergo radiotherapy and systemic therapy as determined by the treating physician.
• Age ≥ 18
• ECOG ≤ 2 (Eastern Cooperative Oncology Group scoring system used to quantify general well-being and activities of daily life; scores range from 0 to 5 where 0 represents perfect health and 5 represents death)
• No prior invasive malignancy in the past 3-years. Exceptions include non-melanomatous skin cancer and in situ cancers of the bladder or head and neck are permissible.
• Subjects must freely sign informed consent to enroll in the study.
• Subjects must use contraception up to 90 days after last drug dose.

You may not qualify if…

• Planned systemic therapy with Radium-223 dichloride or sipuleucel-T
• Tumor requiring emergent radiation in view of provider
• Life expectancy estimate of <3 months
• Presence of known parenchymal brain metastasis
• Uncontrolled intercurrent illness
• Inability to undergo radiotherapy, systemic treatment, CTs or bone scans
• Biopsy proven pure small cell or neuroendocrine prostate cancer

Where it is running

• VA Ann Arbor Healthcare System — Ann Arbor, Michigan, United States
• University of Michigan Cancer Center — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.